Who makes Non-mavacamten symptomatic oHCM therapy?

Non-mavacamten symptomatic oHCM therapy is developed by Bristol-Myers Squibb.

What development phase is Non-mavacamten symptomatic oHCM therapy in?

Non-mavacamten symptomatic oHCM therapy is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Non-mavacamten symptomatic oHCM therapy

Bristol-Myers Squibb · Phase 2 active Small molecule

At a glance

Generic name	Non-mavacamten symptomatic oHCM therapy
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Non-mavacamten symptomatic oHCM therapy CI brief — competitive landscape report
Non-mavacamten symptomatic oHCM therapy updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI